1
|
Alabsi SM, Duval S, Sundberg M, Williams D, Luepker RV, Eder M, Van't Hof JR. Regular aspirin use among a sample of American Indians/Alaskan Natives in the Upper Midwest region of the United States. Prev Med Rep 2024; 37:102571. [PMID: 38222307 PMCID: PMC10784686 DOI: 10.1016/j.pmedr.2023.102571] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/09/2023] [Revised: 12/10/2023] [Accepted: 12/18/2023] [Indexed: 01/16/2024] Open
Abstract
Despite high prevalence of cardiovascular disease (CVD) and CVD risk factors among American Indian or Alaska Native adults (AI/AN), there is little information on aspirin use in this population. This survey-based study seeks to understand prevalence of aspirin use in a sample of AI/AN adults in the Upper Midwestern United States. In-person and telephone based surveys were conducted querying self-reported CVD and CVD risk factors, aspirin use, and aspirin related discussion with clinicians. A total of 237 AI/AN participants were included: mean age (SD) was 60.8 (8.4) years; 143 (60 %) were women; 59 (25 %) reported CVD history. CVD risk factors were common particularly smoking (37 %) and diabetes (37 %). Aspirin use was much higher among those with CVD (secondary prevention, 76 %) than those without (primary prevention, 33 %). Primary prevention aspirin use was significantly associated with age and all CVD risk factors in unadjusted analyses. After adjustment for demographics and CVD risk factors, only age (aRR 1.13 per 5 years, 95 % CI 1.02, 1.25) and diabetes (aRR 2.44, 95 % CI 1.52, 3.92) remained significantly associated with aspirin. Regardless of CVD status, a higher proportion of those taking aspirin reported a conversation about aspirin with their doctor compared to those not taking aspirin. Among participants with no CVD, those who had such a conversation were 2.6 times more likely to use aspirin than those who did not have a conversation (aRR 2.64, 95 % CI 1.58, 4.44). The findings of this study emphasize the importance of the patient-provider relationship for preventive therapy.
Collapse
Affiliation(s)
| | - Sue Duval
- Cardiovascular Division and Lillehei Heart Institute, Department of Medicine, University of Minnesota Medical School, Minneapolis MN, USA
| | - Michael Sundberg
- Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA
| | - Donovan Williams
- Division of Geriatrics, Palliative and Primary Care, University of Minnesota Medical School, Minneapolis MN, USA
| | - Russell V. Luepker
- Cardiovascular Division and Lillehei Heart Institute, Department of Medicine, University of Minnesota Medical School, Minneapolis MN, USA
- University of Minnesota School of Public Health, Division of Epidemiology and Public Health, Minneapolis, MN, USA
| | - Milton Eder
- Department of Family Medicine and Community Health, University of Minnesota Medical School, Minneapolis, MN, USA
| | - Jeremy R. Van't Hof
- Cardiovascular Division and Lillehei Heart Institute, Department of Medicine, University of Minnesota Medical School, Minneapolis MN, USA
| |
Collapse
|
2
|
Mujaj B, Zhang ZY, Yang WY, Thijs L, Wei FF, Verhamme P, Delles C, Butler J, Sever P, Latini R, Gf Cleland J, Zannad F, Staessen JA. Aspirin use is associated with increased risk for incident heart failure: a patient-level pooled analysis. ESC Heart Fail 2021; 9:685-694. [PMID: 34808706 PMCID: PMC8787993 DOI: 10.1002/ehf2.13688] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2021] [Revised: 10/05/2021] [Accepted: 10/14/2021] [Indexed: 01/10/2023] Open
Abstract
Aims Recent trials evaluating the effect of aspirin in the primary prevention of cardiovascular disease showed little or no benefit. However, the role of aspirin on the risk of incident heart failure (HF) remains elusive. This study aimed to evaluate the role of aspirin use on HF incidence in primary and secondary prevention and whether aspirin use increases the risk of incident HF in patients at risk. Methods and results Data from 30 827 patients at risk for HF enrolled in six observational studies were analysed [women 33.9%, mean age (±standard deviation) 66.8 ± 9.2 years]. Cardiovascular risk factors and aspirin use were recorded at baseline, and patients were followed up for the first incident of fatal or non‐fatal HF. The association of incident HF with aspirin use was assessed using multivariable‐adjusted proportional hazard regression, which accounted for study and cardiovascular risk factors. Over 5.3 years (median; 5th–95th percentile interval, 2.1–11.7 years), 1330 patients experienced HF. The fully adjusted hazard ratio (HR) associated with aspirin use was 1.26 [95% confidence interval (CI) 1.12–1.41; P ≤ 0.001]. Further, in a propensity‐score‐matched analysis, the HR was 1.26 (95% CI 1.10–1.44; P ≤ 0.001). In 22 690 patients (73.6%) without history of cardiovascular disease, the HR was 1.27 (95% CI 1.10–1.46; P = 0.001). Conclusions In patients, at risk, aspirin use was associated with incident HF, independent of other risk factors. In the absence of conclusive trial evidence, our observations suggest that aspirins should be prescribed with caution in patients at risk of HF or having HF.
Collapse
Affiliation(s)
- Blerim Mujaj
- Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.,Department of Diagnostic and Interventional Radiology, University Centre, Faculty of Medicine, University of Freiburg, Freiburg, Germany
| | - Zhen-Yu Zhang
- Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium
| | - Wen-Yi Yang
- Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium
| | - Lutgarde Thijs
- Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium
| | - Fang-Fei Wei
- Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium
| | - Peter Verhamme
- Centre for Molecular and Vascular Biology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium
| | - Christian Delles
- Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
| | - Javed Butler
- Department of Medicine, University of Mississippi Medical Centre, Jackson, MS, USA
| | - Peter Sever
- International Centre for Circulatory Health and National Heart and Lung Institute, Imperial College London, London, UK
| | - Roberto Latini
- Department of Cardiovascular Medicine, IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy
| | - John Gf Cleland
- Cardiology Department, Castle Hill Hospital, University of Hull and Imperial College London, London, UK
| | - Faiez Zannad
- INSERM, Centre d'Investigations Cliniques Plurithe'matique 1433, INSERM U1116, CHRU de Nancy, F-CRIN INI-CRCT, Université de Lorraine, Nancy, France
| | - Jan A Staessen
- Research Institute Alliance for the Promotion of Preventive Medicine (APPREMED), Mechelen, Belgium.,Biomedical Science Group, University of Leuven, Leuven, Belgium
| | | |
Collapse
|
3
|
Wang X, Hao G, Chen Z, Zhang L, Kang Y, Yang Y, Zheng C, Zhou H, Chen L, Wang Z, Gao R. Aspirin use in patients with diagnosed diabetes in the United States and China: Nationally representative analysis. Diab Vasc Dis Res 2021; 18:14791641211067416. [PMID: 35135375 PMCID: PMC8867494 DOI: 10.1177/14791641211067416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
BACKGROUND The epidemiological data on the use of aspirin in diabetic patients is very limited. The main purpose of this study is to examine the current status of aspirin use in the United States (US) and China in large representative populations. METHODS Data came from the National Health and Nutrition Examination Survey (NHANES) and China Hypertension Survey (CHS), two nationally representative cross-sectional studies. RESULTS The percentage of aspirin use was 73.8% in US diabetic patients with ASCVD, and the percentage of aspirin use in diabetic patients with high ASCVD risk was marginally higher in men (p = .052), 54.5% in men and 37.1% in women. The percentages of aspirin use in diabetic patients with intermediate and low ASCVD risk were 55.1% and 35.0%, respectively. In China, the percentage of aspirin use in diabetic patients with ASCVD was 53.5%, and were 14.3%, 9.7%, and 3.2% among diabetic patients with high, intermediate, and low ASCVD risk, respectively. CONCLUSIONS In summary, the percentage of aspirin use in primary prevention in US diabetic patients in men was higher than in women, and this percentage for primary and secondary prevention in US patients was higher than that in Chinese patients.
Collapse
Affiliation(s)
- Xin Wang
- Division of Prevention and Community
Health, National Center for Cardiovascular Disease, National Clinical Research Center of
Cardiovascular Disease, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Peking Union Medical College and Chinese Academy
of Medical Sciences, Beijing, China
| | - Guang Hao
- Department of Epidemiology, School of Medicine, Jinan
University, Guangzhou, China
| | - Zuo Chen
- Division of Prevention and Community
Health, National Center for Cardiovascular Disease, National Clinical Research Center of
Cardiovascular Disease, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Peking Union Medical College and Chinese Academy
of Medical Sciences, Beijing, China
| | - Linfeng Zhang
- Division of Prevention and Community
Health, National Center for Cardiovascular Disease, National Clinical Research Center of
Cardiovascular Disease, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Peking Union Medical College and Chinese Academy
of Medical Sciences, Beijing, China
| | - Yuting Kang
- Division of Prevention and Community
Health, National Center for Cardiovascular Disease, National Clinical Research Center of
Cardiovascular Disease, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Peking Union Medical College and Chinese Academy
of Medical Sciences, Beijing, China
| | - Ying Yang
- Division of Prevention and Community
Health, National Center for Cardiovascular Disease, National Clinical Research Center of
Cardiovascular Disease, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Peking Union Medical College and Chinese Academy
of Medical Sciences, Beijing, China
| | - Congyi Zheng
- Division of Prevention and Community
Health, National Center for Cardiovascular Disease, National Clinical Research Center of
Cardiovascular Disease, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Peking Union Medical College and Chinese Academy
of Medical Sciences, Beijing, China
| | - Haoqi Zhou
- Division of Prevention and Community
Health, National Center for Cardiovascular Disease, National Clinical Research Center of
Cardiovascular Disease, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Peking Union Medical College and Chinese Academy
of Medical Sciences, Beijing, China
| | - Lu Chen
- Division of Prevention and Community
Health, National Center for Cardiovascular Disease, National Clinical Research Center of
Cardiovascular Disease, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Peking Union Medical College and Chinese Academy
of Medical Sciences, Beijing, China
| | - Zengwu Wang
- Division of Prevention and Community
Health, National Center for Cardiovascular Disease, National Clinical Research Center of
Cardiovascular Disease, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, Peking Union Medical College and Chinese Academy
of Medical Sciences, Beijing, China
- Zengwu Wang, MD, PhD, Division of Prevention and
Community Health, National Center for Cardiovascular Disease, National Clinical Research
center of Cardiovascular Disease, State Key Laboratory of Cardiovascular Disease, Fuwai
Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, No. 15
(Lin), Fengcunxili, Mentougou District, Beijing 102308, China.
| | - Runlin Gao
- Department of Cardiology, Fuwai Hospital, Peking Union Medical College and Chinese Academy
of Medical Sciences, Beijing, China
| |
Collapse
|
4
|
Okunrintemi V, Benson EA, Derbal O, Miedema MD, Blumenthal RS, Tibuakuu M, Ogunmoroti O, Khan SU, Mamas MA, Gulati M, Michos ED. Age-specific differences in patient reported outcomes among adults with atherosclerotic cardiovascular disease: Medical expenditure panel survey 2006-2015. Am J Prev Cardiol 2020; 3:100083. [PMID: 34327463 DOI: 10.1016/j.ajpc.2020.100083] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2020] [Revised: 08/09/2020] [Accepted: 08/20/2020] [Indexed: 12/02/2022] Open
Abstract
Objective The prevalence of atherosclerotic cardiovascular disease (ASCVD) in younger adults has increased over the past decade. However, it is less well established whether patient reported outcomes differ between younger and older adults with ASCVD. We sought to evaluate age-specific differences in patient reported outcomes among adults with ASCVD. Methods This was a retrospective cross-sectional survey study. We used data from the 2006–2015 Medical Expenditure Panel Survey (MEPS), a nationally representative sample of the United States population. Adults ≥18 years with a diagnosis of ASCVD, ascertained by ICD9 codes or self-reported data, were included. Logistic regression was used to compare self-reported patient-clinician communication, patient satisfaction, perception of health, emergency department (ED) visits, and use of preventive medications (aspirin and statins) by age category [Young: 18–44, Middle: 45–64, Older: ≥65 years]. We used two-part econometric modeling to evaluate age-specific annual healthcare expenditure. Results There were 21,353 participants included. Over 9000 (42.6%-weighted) of the participants were young or middle aged, representing ~9.9 million adults aged <65 years with ASCVD nationwide. Compared with older adults, middle-aged and young adults with ASCVD were more likely to report poor patient-clinician communication [OR 1.73 (95% CI 1.28–2.33) and 2.49 (1.76–3.51), respectively], poor healthcare satisfaction, and poor perception of health status, have increased ED utilization and were also less likely to be using aspirin and statins. The mean annual healthcare expenditure was highest among middle-aged adults [$10,798 (95% CI, $10,012 to $11,583)]. Conclusion Compared with older adults, younger adults with ASCVD were more likely to report poor patient experience and poor health status and less likely to be using preventive medications. More effort needs to be geared towards understanding the age-specific differences in healthcare quality and delivery to improve outcomes among high-risk young adults with ASCVD. In a sample of US adults with ASCVD we compared young & middle-age to older adults. Young adults were more likely to report poor healthcare communication & satisfaction. Young adults at a higher risk for depression and have poorer health perception. Young adults with ASCVD were less likely to be using aspirin and statins. More effort needed to understanding age-specific differences in patient experience.
Collapse
|
5
|
Abstract
Background The use of aspirin has been linked to a reduced risk of cancer at several sites, such as the breast, prostate, and colorectum. However, the evidence for this chemopreventive effect from aspirin use on endometrial cancer is conflicting, and whether an association exists is an open question. Methods After carrying out a database search of articles published up to December 2019, we identified 7 case-control studies and 11 cohort studies, including a total of 14,766 endometrial cancer cases. We pooled the odds ratios (ORs) in case-control studies and risk ratios (RRs) in cohort studies, and then conducted subgroup analysis based on factors such as the frequency and duration of aspirin use, and obesity. Results In the overall meta-analysis, we found a significant inverse association between any aspirin use and the risk of endometrial cancer both in case-control studied [pooled ORs =0.88, 95% confidence interval (CI): 0.78–0.98] and cohort studies (pooled RRs =0.86, 95% CI: 0.86–0.99). In the subgroup analysis, a negative association was observed between the maximal frequency of aspirin use and the endometrial cancer risk (pooled ORs/RRs: 0.82; 95% CI: 0.71–0.95), but no correlations were observed based on the longest duration of aspirin use or obesity. Conclusions Our results suggest that the use of aspirin was associated with a reduced risk of endometrial cancer, and the reduced risk was closely related to the high-frequency of use. Further randomized controlled trials (RCTs) are needed to confirm these findings.
Collapse
Affiliation(s)
- Yang Wang
- Department of Gynecology, Obstetrics & Gynecology Hospital of Fudan University, Shanghai 200011, China
| | - Junda Zhao
- The Outpatient Department of Gynecology, First Teaching Hospital of Xinjiang Medical University, Urumqi 830054, China
| | - Xing Chen
- Department of Gynecology, Obstetrics & Gynecology Hospital of Fudan University, Shanghai 200011, China
| | - Feifei Zhang
- Department of Gynecology, Obstetrics & Gynecology Hospital of Fudan University, Shanghai 200011, China
| | - Xin Li
- Department of Gynecology, Obstetrics & Gynecology Hospital of Fudan University, Shanghai 200011, China
| |
Collapse
|
6
|
Di Maso M, Bosetti C, La Vecchia C, Garavello W, Montella M, Libra M, Serraino D, Polesel J. Regular aspirin use and nasopharyngeal cancer risk: A case-control study in Italy. Cancer Epidemiol 2015; 39:545-7. [PMID: 25960427 DOI: 10.1016/j.canep.2015.04.012] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2015] [Revised: 04/20/2015] [Accepted: 04/22/2015] [Indexed: 11/17/2022]
Abstract
Regular aspirin use has been associated to decreased risk of several cancers, but evidence on nasopharyngeal carcinoma is scanty. We conducted a hospital-based case-control study in Italy, enrolling 198 Caucasian patients with nasopharyngeal carcinoma. Controls were 592 cancer-free Caucasian patients admitted to the same catchment areas as cases; controls were frequency matched according to sex, age, and area of residence. Regular aspirin use was defined as taking at least one aspirin a week for at least 6 months. Three cases (1.5%) and 27 controls (4.5%) reported regular aspirin use (odds ratio=0.24; 95% CI: 0.07-0.87). The median duration of consumption was 15 months among cases and 60 months among controls. Although study findings should be considered with caution due to limited sample size, they provide further evidence on the protective effect of aspirin use in head and neck cancers.
Collapse
Affiliation(s)
- Matteo Di Maso
- Unit of Epidemiology and Biostatistics, CRO Aviano National Cancer Institute, IRCCS, Aviano, Italy
| | - Cristina Bosetti
- Department of Epidemiology, IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy
| | - Carlo La Vecchia
- Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy
| | - Werner Garavello
- Clinica Otorinolaringoiatrica DNTB, Università degli Studi di Milano Bicocca, Milan, Italy
| | - Maurizio Montella
- Unit of Epidemiology, Istituto Tumori "Fondazione Pascale IRCCS", Naples, Italy
| | - Massimo Libra
- Departement of Biomedical Sciences, Università di Catania, Catania, Italy
| | - Diego Serraino
- Unit of Epidemiology and Biostatistics, CRO Aviano National Cancer Institute, IRCCS, Aviano, Italy
| | - Jerry Polesel
- Unit of Epidemiology and Biostatistics, CRO Aviano National Cancer Institute, IRCCS, Aviano, Italy.
| |
Collapse
|